Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations-Reference-Cited by-同舟云学术

Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations

Published:2023-04-16 Issue:8 Volume:72 Page:2613-2621
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Shimoda Yukiko,Yoshida Tatsuya,Miyakoshi Jun,Torasawa Masahiro,Tateishi Akiko,Matsumoto Yuji,Masuda Ken,Shinno Yuki,Okuma Yusuke,Goto Yasushi,Horinouchi Hidehito,Yamamoto Noboru,Ohe Yuichiro

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-023-03429-z.pdf

Reference29 articles.

1. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388. https://doi.org/10.1056/NEJMoa0909530

2. Zhou C, Wu Y-L, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735–742. https://doi.org/10.1016/s1470-2045(11)70184-x

3. Sequist LV, Yang JC-H, Yamamoto N et al (2013) Phase III study of Afatinib or Cisplatin Plus pemetrexed in patients with metastatic lung adenocarcinoma With EGFR mutations. J Clin Oncol 31:3327–3334. https://doi.org/10.1200/jco.2012.44.2806

4. Solomon BJ, Mok T, Kim DW et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177. https://doi.org/10.1056/NEJMoa1408440

5. Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378:2288–2301. https://doi.org/10.1056/NEJMoa1716948

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful Treatment of Switching EGFR-TKIs for Advanced Lung Adenocarcinoma Due to Interstitial Lung Disease: A Case Report;Current Cancer Drug Targets;2024-07-05

2. Longer interval between last ICI dose and first TKI dose reduces risk of SAEs;Reactions Weekly;2023-04-29